KYTX — Kyverna Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1994702 ·
Last close
$8.24
Market Cap
$509.59M
52W High
$10.29
52W Low
$6.98
ADV30
850,168
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -41,367,000 | -39,728,000 | 257,024,000 | 32,194,000 | 61,444,000 |
| Dec 2025 | 0 | — | -39,282,000 | -37,804,000 | 293,826,000 | 124,093,000 | 61,550,000 |
| Sep 2025 | 0 | — | -38,727,000 | -36,787,000 | 187,156,000 | 34,164,000 | 35,210,000 |
| Jun 2025 | 0 | — | -44,410,000 | -42,081,000 | 226,508,000 | 53,440,000 | 42,131,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-150,394,000
Investing CF
$-15,764,000
Financing CF
$141,481,000
CapEx
$-1,461,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.28
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-464,555,000
Inventory
—
Receivables
—
ST Investments
$204,252,000
EBIT TTM
$-155,268,000
Pretax Income TTM
$-156,400,000
Interest Exp TTM
$1,132,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -169,827,000 | -161,307,000 | 293,826,000 | 61,550,000 | — | -153,712,000 |
| Dec 2024 | 0 | -142,604,000 | -127,477,000 | 304,645,000 | 38,058,000 | — | -114,250,000 |
| Dec 2023 | 0 | -62,406,000 | -60,366,000 | 75,195,000 | 206,592,000 | — | -52,410,000 |
| Dec 2022 | 7,025,000 | -29,384,000 | -28,893,000 | 66,924,000 | 140,921,000 | — | -36,113,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.07
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $8.24 · call volume: 95 · put volume: 376
Expected Move to 2027-03-19:
±$5.80
(70.39%) —
implied range
$2.44 –
$14.04
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CCCC | C4 Therapeutics, Inc. | $504.40M | $4.10 | — |
| CABA | Cabaletta Bio, Inc. | $525.59M | $3.10 | — |
| RGNX | REGENXBIO Inc. | $531.74M | $8.06 | — |
| OCGN | Ocugen, Inc. | $461.19M | $1.36 | — |
| ARTV | Artiva Biotherapeutics, Inc. | $563.21M | $11.52 | — |
News headlines (Yahoo Finance, 1h cache)
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
2026-08-11 20:02 · Yahoo
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
2026-07-27 12:00 · Yahoo
Kyverna Therapeutics Sinks 13%: Here’s Why
2026-07-10 19:59 · Yahoo
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
2026-06-22 12:00 · Yahoo
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
2026-06-08 18:54 · Yahoo
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
2026-06-03 12:00 · Yahoo
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
2026-05-18 12:00 · Yahoo
Kyverna Therapeutics to Present at Upcoming Investor Conferences
2026-05-14 12:00 · Yahoo
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
2026-05-04 12:00 · Yahoo
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Brea
2026-04-21 22:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.